201 related articles for article (PubMed ID: 17999742)
21. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
[TBL] [Abstract][Full Text] [Related]
23. Current clinical management of gastrointestinal stromal tumors.
Tosoni A; Nicolardi L; Brandes AA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.
Eckel F; von Delius S; Mayr M; Dobritz M; Fend F; Hosius C; Schleyer E; Schulte-Frohlinde E; Schmid RM; Lersch C
Oncology; 2005; 69(5):363-71. PubMed ID: 16319507
[TBL] [Abstract][Full Text] [Related]
25. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
26. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
27. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma.
Wright JH; Johnson MM; Shimizu-Albergine M; Bauer RL; Hayes BJ; Surapisitchat J; Hudkins KL; Riehle KJ; Johnson SC; Yeh MM; Bammler TK; Beyer RP; Gilbertson DG; Alpers CE; Fausto N; Campbell JS
Int J Cancer; 2014 Feb; 134(4):778-88. PubMed ID: 23929039
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice.
Okada H; Honda M; Campbell JS; Takegoshi K; Sakai Y; Yamashita T; Shirasaki T; Takabatake R; Nakamura M; Tanaka T; Kaneko S
Cancer Sci; 2015 Sep; 106(9):1143-52. PubMed ID: 26122702
[TBL] [Abstract][Full Text] [Related]
29. Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells.
Pirraco A; Coelho P; Rocha A; Costa R; Vasques L; Soares R
J Cell Biochem; 2010 Oct; 111(2):433-41. PubMed ID: 20518073
[TBL] [Abstract][Full Text] [Related]
30. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
32. [WT inhibit human hepatocellular carcinoma BEL-7402 cells growth by modulating Akt and ERK1/2 phosphorylation].
Zhang Z; Duan C; Ding K; Wang Z
Zhongguo Zhong Yao Za Zhi; 2009 Dec; 34(24):3277-80. PubMed ID: 20353018
[TBL] [Abstract][Full Text] [Related]
33. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma.
Campbell JS; Hughes SD; Gilbertson DG; Palmer TE; Holdren MS; Haran AC; Odell MM; Bauer RL; Ren HP; Haugen HS; Yeh MM; Fausto N
Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3389-94. PubMed ID: 15728360
[TBL] [Abstract][Full Text] [Related]
34. Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors.
Ito T; Ogawa R; Uezumi A; Ohtani T; Watanabe Y; Tsujikawa K; Miyagoe-Suzuki Y; Takeda S; Yamamoto H; Fukada S
Neuromuscul Disord; 2013 Apr; 23(4):349-56. PubMed ID: 23313020
[TBL] [Abstract][Full Text] [Related]
35. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
[TBL] [Abstract][Full Text] [Related]
36. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha.
Ohashi A; Kinoshita K; Isozaki K; Nishida T; Shinomura Y; Kitamura Y; Hirota S
Int J Cancer; 2004 Sep; 111(3):317-21. PubMed ID: 15221957
[TBL] [Abstract][Full Text] [Related]
37. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
[TBL] [Abstract][Full Text] [Related]
38. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
39. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion.
Fitter S; Vandyke K; Gronthos S; Zannettino AC
J Mol Endocrinol; 2012 Jun; 48(3):229-40. PubMed ID: 22474082
[TBL] [Abstract][Full Text] [Related]
40. Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRα activity.
Ma LK; Li Q; He LF; Hua JS; Zhou JL; Yu H; Feng KF; Chen HW; Hu H; Wang L
Arq Bras Cardiol; 2012 Dec; 99(6):1082-91. PubMed ID: 23184075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
